Humanized CAR binding domains to minimize immunogenicity Ultra-modular CAR design to enhance efficacy and function Multi-step safety switch to enhance safety and physician control Ultra-fast manufacture: the first ‘24-hour CAR-T product’

What we do

T-CURX develops new generation UltraModularCARTM T cells for personalized cancer immunotherapy, built on cutting-edge technologies that overcome challenges in safety & efficacy, manufacture & scalability of conventional CAR-T.

T-CURX’ UltraModularCARTM T cells are a transformative, one-shot, chemotherapy-free cancer treatment. Patient T cells are reprogrammed using revolutionary gene transfer technology to destroy tumor cells. UltraModularCARTM T cells are ‘living drugs’ that persist life-long and provide protection from relapse.

T-CURX’ target pipeline addresses several unique cancer indications. The lead product is targeting breast and lung cancer (oncology), chronic leukemia and mantle cell lymphoma (hematology). T-CURX has a solid IP portfolio on its platform technologies, established manufacturing capability and positive reviews from regulators, enabling rapid progress towards initiation of clinical POC studies.

Key facts

Indication

Status

Intellectual Property status

Milestones